Hancock Holding Co. reduced its position in Becton Dickinson and Co (NYSE:BDX) by 3.9% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 62,265 shares of the medical instruments supplier’s stock after selling 2,520 shares during the period. Hancock Holding Co.’s holdings in Becton Dickinson and were worth $13,493,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Amica Retiree Medical Trust lifted its holdings in shares of Becton Dickinson and by 325.0% in the 4th quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock valued at $109,000 after purchasing an additional 390 shares during the last quarter. Almanack Investment Partners LLC. purchased a new stake in shares of Becton Dickinson and in the 4th quarter valued at about $109,000. Advisors Preferred LLC purchased a new stake in shares of Becton Dickinson and in the 4th quarter valued at about $126,000. Truewealth LLC purchased a new stake in shares of Becton Dickinson and in the 4th quarter valued at about $133,000. Finally, Penserra Capital Management LLC purchased a new stake in shares of Becton Dickinson and in the 4th quarter valued at about $136,000. 84.26% of the stock is owned by institutional investors and hedge funds.

NYSE BDX opened at $232.57 on Tuesday. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.12 and a current ratio of 1.70. Becton Dickinson and Co has a 12-month low of $187.27 and a 12-month high of $248.39. The company has a market cap of $61.95 billion, a price-to-earnings ratio of 24.53, a price-to-earnings-growth ratio of 1.61 and a beta of 1.12.

Becton Dickinson and (NYSE:BDX) last released its earnings results on Thursday, May 3rd. The medical instruments supplier reported $2.65 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.63 by $0.02. Becton Dickinson and had a positive return on equity of 14.27% and a negative net margin of 0.46%. The company had revenue of $4.22 billion for the quarter, compared to analysts’ expectations of $4.12 billion. During the same quarter in the previous year, the firm posted $2.30 EPS. The firm’s quarterly revenue was up 42.2% on a year-over-year basis. equities research analysts forecast that Becton Dickinson and Co will post 10.99 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 29th. Shareholders of record on Friday, June 8th will be given a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a yield of 1.29%. The ex-dividend date of this dividend is Thursday, June 7th. Becton Dickinson and’s payout ratio is 31.65%.

In other Becton Dickinson and news, Director David F. Melcher bought 500 shares of the company’s stock in a transaction on Monday, May 7th. The shares were bought at an average price of $225.07 per share, for a total transaction of $112,535.00. Following the transaction, the director now owns 2,728 shares of the company’s stock, valued at approximately $613,990.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Alexandre Conroy sold 20,128 shares of the business’s stock in a transaction that occurred on Monday, May 21st. The stock was sold at an average price of $228.74, for a total value of $4,604,078.72. Following the transaction, the insider now owns 35,583 shares in the company, valued at approximately $8,139,255.42. The disclosure for this sale can be found here. Insiders own 1.00% of the company’s stock.

BDX has been the subject of several analyst reports. BMO Capital Markets initiated coverage on Becton Dickinson and in a research note on Monday, March 5th. They set a “market perform” rating and a $249.00 price objective for the company. Zacks Investment Research downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Tuesday, March 6th. Citigroup raised Becton Dickinson and from a “neutral” rating to a “buy” rating and upped their price objective for the company from $237.00 to $251.00 in a research note on Tuesday, April 10th. Finally, ValuEngine raised Becton Dickinson and from a “hold” rating to a “buy” rating in a research note on Wednesday, April 18th. Six analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $241.19.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.